Major Depressive Disorder Pipeline Insights Report, 2024 Featuring 75+ Companies and Pipeline Drugs, Including SAGE-217 (Sage Therapeutics) and REL-1017 (Relmada Therapeutics)
08 mai 2024 04h43 HE
|
Research and Markets
Dublin, May 08, 2024 (GLOBE NEWSWIRE) -- The "Major Depressive Disorder - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...